(PFE) Pfizer - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Stock:

Total Rating 50

Risk 80

Buy Signal 0.26

Drug Manufacturers - General +5.1
Pharmaceuticals +6.1

Market Cap: 152,718m
Avg Trading Vol: 1.20B USD

ATR: 2.29%
Peers RS (IBD): 38.61

Risk 5d forecast
Volatility	25.0%
Relative Tail Risk	-5.34%

Reward TTM
Sharpe Ratio	0.35
Alpha	3.93

Character TTM
Beta	0.448
Beta Downside	0.810

Drawdowns 3y
Max DD	42.27%
CAGR/Max DD	-0.18

EPS (Earnings per Share)

EPS CAGR: -21.29%
EPS Trend: -37.7%

Last SUE: 0.94
Qual. Beats: 9

Revenue

Rev. CAGR: -9.63%
Rev. Trend: -58.2%

Last SUE: 0.37
Qual. Beats: 0

Description: PFE Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz, PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income: 7.77b TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.42 > 1.0
NWC/Revenue: 16.50% < 20% (prev 11.57%; Δ 4.93% < -1%)
CFO/TA 0.03 > 3% & CFO 6.36b > Net Income 7.77b
Net Debt (61.71b) to EBITDA (15.10b): 4.09 < 3
Current Ratio: 1.28 > 1.5 & < 3
Outstanding Shares: last quarter (5.69b) vs 12m ago -0.30% < -2%
Gross Margin: 70.33% > 18% (prev 0.67%; Δ 6967 % > 0.5%)
Asset Turnover: 29.65% > 50% (prev 29.82%; Δ -0.17% > 0%)
Interest Coverage Ratio: 3.20 > 6 (EBITDA TTM 15.10b / Interest Expense TTM 2.67b)

Altman Z'' 3.33

A: 0.05 (Total Current Assets 46.92b - Total Current Liabilities 36.60b) / Total Assets 208.73b
B: 0.58 (Retained Earnings 121.15b / Total Assets 208.73b)
C: 0.04 (EBIT TTM 8.53b / Avg Total Assets 211.06b)
D: 0.80 (Book Value of Equity 92.80b / Total Liabilities 115.64b)
Altman-Z'' Score: 3.33 = A

Beneish M

DSRI: none (Receivables none/14.78b, Revenue 62.58b/63.63b)
GMI: 0.95 (GM 70.33% / 66.76%)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: 0.98 (Revenue 62.58b / 63.63b)
TATA: 0.01 (NI 7.77b - CFO 6.36b) / TA 208.73b)
Beneish M-Score: cannot calculate (missing components)

What is the price of PFE shares?

As of February 24, 2026, the stock is trading at USD 27.06 with a total of 33,993,700 shares traded.
Over the past week, the price has changed by -1.13%, over one month by +5.50%, over three months by +9.09% and over the past year by +8.91%.

Is PFE a buy, sell or hold?

Pfizer has received a consensus analysts rating of 3.56. Therefor, it is recommend to hold PFE.

StrongBuy: 7
Buy: 2
Hold: 15
Sell: 0
StrongSell: 1

What are the forecasts/targets for the PFE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	28.6	5.5%
Analysts Target Price	28.6	5.5%

PFE Fundamental Data Overview February 21, 2026

P/E Trailing = 19.75
P/E Forward = 9.311
P/S = 2.4404
P/B = 1.6898
P/EG = 3.7725
Revenue TTM = 62.58b USD
EBIT TTM = 8.53b USD
EBITDA TTM = 15.10b USD
Long Term Debt = 56.55b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.30b USD (from shortTermDebt, two quarters ago)
Debt = 61.71b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 61.71b USD (using Total Debt 61.71b, CCE unavailable)
Enterprise Value = 214.43b USD (152.72b + Debt 61.71b - (null CCE))
Interest Coverage Ratio = 3.20 (Ebit TTM 8.53b / Interest Expense TTM 2.67b)
EV/FCF = 46.90x (Enterprise Value 214.43b / FCF TTM 4.57b)
FCF Yield = 2.13% (FCF TTM 4.57b / Enterprise Value 214.43b)
FCF Margin = 7.31% (FCF TTM 4.57b / Revenue TTM 62.58b)
Net Margin = 12.42% (Net Income TTM 7.77b / Revenue TTM 62.58b)
Gross Margin = 70.33% ((Revenue TTM 62.58b - Cost of Revenue TTM 18.57b) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 74.95%)
Tobins Q-Ratio = 1.03 (Enterprise Value 214.43b / Total Assets 208.73b)
Interest Expense / Debt = 1.15% (Interest Expense 711.0m / Debt 61.71b)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.74b (EBIT 8.53b * (1 - 21.00%))
Current Ratio = 1.28 (Total Current Assets 46.92b / Total Current Liabilities 36.60b)
Debt / Equity = 0.66 (Debt 61.71b / totalStockholderEquity, last quarter 93.10b)
Debt / EBITDA = 4.09 (Net Debt 61.71b / EBITDA 15.10b)
Debt / FCF = 13.50 (Net Debt 61.71b / FCF TTM 4.57b)
Total Stockholder Equity = 91.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.68% (Net Income 7.77b / Total Assets 208.73b)
RoE = 8.52% (Net Income TTM 7.77b / Total Stockholder Equity 91.23b)
RoCE = 5.77% (EBIT 8.53b / Capital Employed (Equity 91.23b + L.T.Debt 56.55b))
RoIC = 4.45% (NOPAT 6.74b / Invested Capital 151.63b)
WACC = 5.65% (E(152.72b)/V(214.43b) * Re(7.57%) + D(61.71b)/V(214.43b) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.34%
[DCF Debug] Terminal Value 83.67% ; FCFF base≈6.68b ; Y1≈5.30b ; Y5≈3.54b
Fair Price DCF = 8.29 (EV 108.83b - Net Debt 61.71b = Equity 47.11b / Shares 5.69b; r=5.90% [WACC]; 5y FCF grow -24.64% → 2.90% )
EPS Correlation: -37.73 | EPS CAGR: -21.29% | SUE: 0.94 | # QB: 9
Revenue Correlation: -58.19 | Revenue CAGR: -9.63% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.73 | Chg30d=-0.018 | Revisions Net=-3 | Analysts=17
EPS current Year (2026-12-31): EPS=2.96 | Chg30d=-0.011 | Revisions Net=-1 | Growth EPS=-8.0% | Growth Revenue=-2.4%
EPS next Year (2027-12-31): EPS=2.83 | Chg30d=-0.018 | Revisions Net=-1 | Growth EPS=-4.3% | Growth Revenue=-3.4%

Additional Sources for PFE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle